Despite substantial progress in understanding the molecular pathology of Parkinson’s disease (PD), the underlying drivers of PD in many cases remain unknown. Here, we investigate the role of RNA modification in PD, following observations of selective m
6
A hypomethylation in the substantia nigra (SN) of mouse PD models and dysregulated
METTL3
and
ALKBH5
expression in dopaminergic (DA) neurons from patients with PD. We found preferential m
6
A deposition on transcripts of PD risk genes and what we believe to be a previously unreported heterozygous METTL3 p.K480R mutation in patients with PD.
Mettl3K480R/+
mice exhibited progressive METTL3 reduction and m
6
A hypomethylation in the SN, leading to progressive DA neuron loss, phospho-α-synuclein increase, and levodopa-responsive motor and nonmotor deficits, mimicking PD progression. Dopamine transporter–specific METTL3 knockout mice recapitulate m
6
A hypomethylation, neurodegeneration, and levodopa-responsive parkinsonism. Mechanistically, m
6
A deficiency disrupted mitochondrial biogenesis and function through regulating
Tfam
expression, while mitochondrial dysfunction reciprocally impaired m
6
A deposition, creating a pathogenic loop. Importantly, supplementation with S-adenosylmethionine (SAMe) enhanced m
6
A modification, disrupted the pathogenic loop, and alleviated parkinsonism in mouse models. Our findings revealed m
6
A dysregulation as an important contributor to PD pathogenesis, provide a valuable preclinical mouse model for PD progression, and highlight RNA methylation-targeted therapies as a promising strategy for PD intervention.